Arcus Biosciences
RCUS
179 hedge funds and large institutions have $1.01B invested in Arcus Biosciences in 2023 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 70 increasing their positions, 60 reducing their positions, and 43 closing their positions.
37% more call options, than puts
Call options by funds: $10.2M | Put options by funds: $7.43M
17% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 60
1.66% more ownership
Funds ownership: 74.27% → 75.93% (+1.7%)
7% less capital invested
Capital invested by funds: $1.09B → $1.01B (-$79.4M)
11% less funds holding
Funds holding: 200 → 179 (-21)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
44% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 43
Top Buyers
| 1 |
State Street
Boston,
Massachusetts
|
+$37.3M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$21.5M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$19.3M |
| 4 |
BlackRock
New York
|
+$14.3M |
| 5 |
Walleye Capital
New York
|
+$7.94M |
Top Sellers
RCUS Hedge Fund Activity: Q1 2023 in Review
179 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q1 2023, worth a combined $1.01B — down 7.3% from $1.09B a quarter earlier.
Sellers outnumbered buyers: 43 funds closed out of RCUS and 24 opened new positions — a net loss of 19 holders — while 60 trimmed existing stakes and 70 added.
The largest buyer was State Street, adding an estimated $37.3M. The largest seller was BVF Inc, exiting entirely with an estimated $47.6M sold.
- 179 institutional investors held Arcus Biosciences (RCUS) as of Q1 2023, down from 200 in Q4 2022.
- Funds reported $1.01B of Arcus Biosciences stock for Q1 2023, down 7.3% quarter-over-quarter.
- 24 funds opened new Arcus Biosciences positions in Q1 2023 and 43 closed out, a net change of -19 holders.
- The largest Arcus Biosciences buyer in Q1 2023 was State Street, an estimated $37.3M added.
- The largest Arcus Biosciences seller in Q1 2023 was BVF Inc, an estimated $47.6M sold.
Based on aggregated 13F filings for Q1 2023.